MedWatch

Digital consumer care to help ALK capture markets

ALK's new digital platforms are to prove their worth for the first time, when the Danish allergy group launches a new core product in autumn. The company aims to speed up sales via online search analysis, apps and patient websites.

Foto: Niels Ahlmann Olesen / Ritzau Scanpix/

Earlier this summer, Danish allergy firm ALK obtained approval of its tablet vaccine against tree pollen allergy in 17 European countries. The new tablet vaccine, Itulazax, is expected to enter the first markets already this autumn, and ALK is now using new methods to kick off sales and win the market.

Digital apps, online tools and tracking consumer behavior online are just some of the initiatives to attract patients' attention to the company's tablet vaccine.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier